Cancerworld Magazine
  • About the Magazine
    • Editorial Team
    • Leadership and Management
    • Events
    • Magazine
    • Archive
    • Contacts
  • Articles
    • Policy
    • Practice Points
    • Delivery of Care
    • Biology basic
    • Medicine
    • Featured
  • Contents
    • News
    • Editorials
    • Interviews to the Expert
    • In the Hot Seat
    • Profiles
    • Obituaries
    • Voices
    • Partnership
    • Supported contents
  • Media Corner
    • Journalist Cancer Guide
    • Cancer Journalism Award
    • Cancer Journalist Grant
SUBSCRIBE FOR FREE
Facebook
Twitter
LinkedIn
Cancerworld Magazine
Cancerworld Magazine
  • About the Magazine
    • Editorial Team
    • Leadership and Management
    • Events
    • Magazine
    • Archive
    • Contacts
  • Articles
    • Policy
    • Practice Points
    • Delivery of Care
    • Biology basic
    • Medicine
    • Featured
  • Contents
    • News
    • Editorials
    • Interviews to the Expert
    • In the Hot Seat
    • Profiles
    • Obituaries
    • Voices
    • Partnership
    • Supported contents
  • Media Corner
    • Journalist Cancer Guide
    • Cancer Journalism Award
    • Cancer Journalist Grant
Cancerworld Magazine > News > Study suggests prehabilitation should become standard of care in oesophageal cancer
  • News

Study suggests prehabilitation should become standard of care in oesophageal cancer

  • 4 February 2022
  • Janet Fricker
Study suggests prehabilitation should become standard of care in oesophageal cancer
Total
0
Shares
0
0
0
0
0

Enrolling oesophageal cancer patients in prehabilitation exercise programmes can boost tumour regression during chemotherapy. The small study, published in British Journal of Sports Medicine (online 1 February, 2022), demonstrated improved pathological, radiological and immunological responses to chemotherapy for those in the exercise group.

“Numerous biochemical and CT-based parameters differed between the intervention and control groups, suggesting reduced inflammation, improved immune function and improved body composition in the intervention group,” write the authors. Chemotherapy response had not been the primary outcome of interest in the study, but when the results started coming through, the investigators found them difficult to ignore. The findings strengthen arguments for prehabilitation to become standard of care for everyone undergoing cancer treatment, not just those on surgical pathways.

In stage 2 and 3 oesophageal cancer, neoadjuvant chemotherapy offers the potential to downstage tumours prior to surgery. However, while the approach makes tumours easier to remove, it also has negative effects of increasing sarcopenia (accelerated loss of muscle mass). Together with visceral obesity, sarcopenia has been associated with both cancer progression and poor response to chemotherapy. Recent animal studies have reported a positive impact of exercise on tumour volume shrinkage.

In the current study, Andrew Davies, a gastro intestinal surgeon, from Guy’s and St Thomas Hospital, London, found evidence for histopathological benefits of exercise in patients with oesophageal cancer undergoing neoadjuvant chemotherapy. For the study, 40 patients were randomised to the intervention group (n=21) or control group (n=19). The exercise programme was based on a ‘moderate intensity’ programme, incorporating aerobic and strength training, with perceived exertion ratings of 4‒5 (where 0 represents no exertion and 10 maximum effort). Sessions took place five to six times per week at a gym, providing a total of 150 weekly minutes of activity, up to the last day before surgery. Investigators then reviewed tumour samples, CT scans and immune markers from patients.

Results showed:

  • 75% of patients in the intervention group achieved Mandard TRG 1‒3 (delineating tumour regression) vs 36.8% in the control group (P=0.025),
  • Combined tumour and node downstaging occurred in 42.8% of patients in the intervention arm vs 15.8% in the control arm (P=0.089),
  • Patients in the intervention group had an improved median fat-to-muscle ratio of -7.15% after prehabilitation vs +12.4% for the control group,
  • The intervention group showed significantly higher markers of immunity (CD-3 and CD-8), than the control group, and lower levels of markers of inflammation (IL-6, VEGF, INF-y, TNFa, MCP-1 and EGF).

“The results from this analysis, showing improvements in pathological regression in the primary tumour and clinical downstaging, are hypothesis generating and the first to be demonstrated in a clinical trial in oesophageal cancer,” write the authors.

The study, they add, furthermore suggests structured exercise interventions could be used to ameliorate treatment-related deconditioning and improve body composition of cancer patients. “This potentially increases the choices for treatment in a greater number of patients with cancer,” write the authors.

Considering the mechanism of action, the authors speculate that the higher content of blood and oxygen delivered to the peripheral tissues of exercising patients might also improve delivery of chemotherapy to tumours.

Given the small number of patients in the study and the fact that it was not randomised, they add, further work is urgently required to confirm or refute these findings.

Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Related Topics
  • chemotherapy
  • downstaging
  • exercises
  • fat-to-muscle ratio
  • neoadjuvant chemotherapy
  • oesophageal cancer
  • prehabilitation
  • sarcopenia
  • tumour regression
Janet Fricker

Janet Fricker is a medical writer specialising in oncology and cardiology. After researching articles for Cancerworld she runs, swims, and eats porridge.

Previous Article
  • News

Citizen science: Do your bit for cancer research by playing a game

  • 4 February 2022
  • Janet Fricker
View Post
Next Article
  • Articles
  • Delivery of Care

Chemobrain: it’s real, it’s troublesome and it deserves more attention

  • 4 February 2022
  • Sophie Fessl
View Post
You May Also Like
View Post
  • News

Study highlights need to reanalyse genomics and genetics of metastatic tumours

  • Janet Fricker
  • 27 January 2023
View Post
  • News

Current cervical cancer screening paradigm fails older women

  • Janet Fricker
  • 26 January 2023
View Post
  • News

Call-to-arms for Europe to provide essential paediatric anti-cancer medicines

  • Janet Fricker
  • 9 January 2023
View Post
  • News

Exercise-stimulated myokine production can extend survival in advanced prostate cancer

  • Janet Fricker
  • 9 January 2023
View Post
  • News

Five San Antonio take-aways to improve care of breast cancer patients

  • Janet Fricker
  • 16 December 2022
View Post
  • News

Repurposed drug combination reduces risk of recurrence following surgery for colorectal cancer

  • Janet Fricker
  • 16 December 2022
View Post
  • News

Aerobic activity to outcompete metastasis 

  • Janet Fricker
  • 2 December 2022
View Post
  • News

Ending cancer inequalities: European summit showcases new tools to inform policy

  • Anna Wagstaff
  • 30 November 2022

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

search
or search in Cancerworld archive
Newsletter

Subscribe free to
Cancerworld!

We'll keep you informed of the latest features and news with a fortnightly email

Subscribe now
Latest News
  • Study highlights need to reanalyse genomics and genetics of metastatic tumours
    • 27 January 2023
  • Current cervical cancer screening paradigm fails older women
    • 26 January 2023
  • Call-to-arms for Europe to provide essential paediatric anti-cancer medicines
    • 9 January 2023
  • Exercise-stimulated myokine production can extend survival in advanced prostate cancer
    • 9 January 2023
  • Five San Antonio take-aways to improve care of breast cancer patients
    • 16 December 2022
Article
  • The cancer patients still struggling to access drugs in the wake of anti-corruption reforms
    • 27 January 2023
  • Immunotherapy: outcomes of ultra low-dose trial offer hope for better global access
    • 26 January 2023
  • Cervical cancer elimination efforts boosted by simpler ways to identify and treat pre-cancerous lesions
    • 12 January 2023
Latest printed issue
Social

Would you follow us ?

Contents
  • AI in Genomics and Reporting for Clinical Practice
    • 26 January 2023
  • Telemedicine in Cancer Care: Monitoring, Follow-Up,Tele-Rehabilitation, Palliative and Supportive Care
    • 23 January 2023
  • AI application in diagnosis
    • 11 January 2023
MENU
  • About the Magazine
    • Editorial Team
    • Leadership and Management
    • Events
    • Magazine
    • Archive
    • Contacts
  • Articles
    • Policy
    • Practice Points
    • Delivery of Care
    • Biology basic
    • Medicine
    • Featured
  • Contents
    • News
    • Editorials
    • Interviews to the Expert
    • In the Hot Seat
    • Profiles
    • Obituaries
    • Voices
    • Partnership
    • Supported contents
  • Media Corner
    • Journalist Cancer Guide
    • Cancer Journalism Award
    • Cancer Journalist Grant
Cancerworld Magazine
  • About the Magazine
  • Articles
  • Media Corner
  • Privacy Policy
  • Cookie Policy

Cancerworld is funded by SPCC Sharing Progress in Cancer Care | Via Vincenzo Vela 6, 6500 Bellinzona - Switzerland | info@spcc.net

Archivio Cancerworld

Input your search keywords and press Enter.